Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of “Buy” by Analysts

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) have been given a consensus recommendation of “Buy” by the fourteen brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $55.1667.

XENE has been the topic of several research reports. Wolfe Research initiated coverage on Xenon Pharmaceuticals in a research note on Monday. They issued an “outperform” rating and a $60.00 target price on the stock. JPMorgan Chase & Co. upped their price objective on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Chardan Capital upgraded shares of Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, November 19th. Stifel Nicolaus set a $66.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Friday, January 9th.

Insider Activity

In other news, CEO Ian Mortimer sold 40,000 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total value of $1,777,200.00. Following the completion of the transaction, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at $266,580. This trade represents a 86.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 65,302 shares of company stock worth $2,924,128 in the last quarter. Corporate insiders own 4.07% of the company’s stock.

Institutional Trading of Xenon Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC purchased a new position in Xenon Pharmaceuticals during the 4th quarter valued at about $33,000. Blue Trust Inc. lifted its holdings in shares of Xenon Pharmaceuticals by 2,560.7% in the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 717 shares in the last quarter. Danske Bank A S bought a new position in shares of Xenon Pharmaceuticals in the third quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd purchased a new position in Xenon Pharmaceuticals during the fourth quarter valued at approximately $43,000. Finally, Aster Capital Management DIFC Ltd bought a new stake in Xenon Pharmaceuticals during the 3rd quarter worth approximately $39,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Stock Up 4.8%

Shares of XENE stock opened at $44.79 on Friday. The firm has a market cap of $3.46 billion, a P/E ratio of -11.51 and a beta of 0.96. The company has a 50 day moving average of $42.45 and a 200-day moving average of $40.89. Xenon Pharmaceuticals has a 12-month low of $26.74 and a 12-month high of $46.60.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.